Download PDF

Clinical Trial Results:
A Phase I/II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity, and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Disease

Summary
EudraCT number	2008-006257-40
Trial protocol	FI SE DK
Global end of trial date	16 Oct 2018

Results information
Results version number	v1(current)
This version publication date	28 Oct 2019
First version publication date	28 Oct 2019
Other versions

Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information

Collapse all Expand all

Trial information

Top of page

Sponsor protocol code

ACI-24-0701

ISRCTN number

US NCT number

WHO universal trial number (UTN)

Sponsor organisation name

AC Immune SA

Sponsor organisation address

EPFL Innovation Park - Building B, Lausanne, Switzerland, 1015

Public contact

Clinical Project Manager, AC Immune SA, +41 213459121, clinicaltrials@acimmune.com

Scientific contact

Clinical Project Manager, AC Immune SA, +41 213459121, clinicaltrials@acimmune.com

Is trial part of an agreed paediatric investigation plan (PIP)

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?

Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?

Analysis stage

Final

Date of interim/final analysis

21 Dec 2018

Is this the analysis of the primary completion data?

Yes

Primary completion date

16 Oct 2018

Global end of trial reached?

Yes

Global end of trial date

16 Oct 2018

Was the trial ended prematurely?

Main objective of the trial

The overall study objective was to assess the safety, immunogenicity, and efficacy of repeated doses of ACI-24 at 4 different dose levels administered to patients with mild to moderate Alzheimer’s disease (AD). The study was a 2-step seamless adaptive design study. Four doses were tested for safety and biological efficacy (Step 1). The most effective dose, assuming adequate safety, was intended to be expanded in Step 2 to obtain proof of concept in terms of cognitive efficacy. Step 2 was not performed.

Protection of trial subjects

Only patients able to give informed consent were enrolled and patients had to be cared by a reliable spouse or other live-in caregiver who gave written consent to assist with clinical assessments and reports safety issues. An interval of at least 1 week between first dose administration in the first 4 patients in each cohort enhanced safety. Furthermore, the dose-cohorts were studied in a sequential manner, each cohort had to complete 4 immunizations and safety data including data 2 weeks after the fourth injection (ie, at visit 8 [Week 14]) were reviewed by the Data Safety Monitoring Board (DSMB) before enrolment into the next cohort commenced. Note regarding long term Follow-up duration: The safety Follow-up period was reduced from 2 to 1 year for patients of Cohort 4 who received an additional boosting dose (dose 8) since no safety concerns were observed in Cohorts 1-3.

Background therapy

Evidence for comparator

Actual start date of recruitment

18 Jan 2010

Long term follow-up planned

Yes

Long term follow-up rationale

Safety

Long term follow-up duration

2 Years

Independent data monitoring committee (IDMC) involvement?

Yes

Number of subjects enrolled per country

Country: Number of subjects enrolled

Sweden: 21

Country: Number of subjects enrolled

Denmark: 12

Country: Number of subjects enrolled

Finland: 15

Worldwide total number of subjects

EEA total number of subjects

Number of subjects enrolled per age group

In utero

Preterm newborn - gestational age < 37 wk

Newborns (0-27 days)

Infants and toddlers (28 days-23 months)

Children (2-11 years)

Adolescents (12-17 years)

Adults (18-64 years)

From 65 to 84 years

85 years and over

Subject disposition

Top of page

Recruitment details

Patients were recruited at 5 sites in 3 countries (Denmark, Finland, and Sweden). Cohort 1 FPFV - LPLV: 18Jan2010 - 05Sep2013 Cohort 2 FPFV - LPLV: 19May2011 - 03Nov2014 Cohort 3 FPFV - LPLV: 02May2012 - 14Nov2016 Cohort 4 FPFV - LPLV: 19May2014 - 16Oct2018 (FPFV = First patient first visit, LPLV = Last patient last visit)

Screening details

Informed consent was obtained before a patient started any study-related procedures. 65 patients were screened and 48 patients were randomized to active treatment or placebo.

Period 1 title

Overall trial (overall period)

Is this the baseline period?

Yes

Allocation method

Randomised - controlled

Blinding used

Double blind

Roles blinded

Subject, Investigator, Carer, Assessor

Blinding implementation details

The study was blinded to patients and site personnel, except to unblinded clinical personnel administrating/preparing the IMP, to pharmacists and to the unblinded CRAs. In emergency circumstances where the investigator was to identify an urgent clinical need to know whether the patient was receiving active medication or placebo, the IVRS was to allow the immediate unblinding of the patient by the investigator directly. Immediate unblinding was not required during the study.

Are arms mutually exclusive

Yes

Cohort 1

Arm description

9 patients were planned to receive 7 doses of ACI-24 at 10μg at weeks 0, 4, 8, 12, 24, 36, and 48. Treatment period: 52 weeks Follow-up period: 100 weeks

Arm type

Experimental

Investigational medicinal product name

ACI-24

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

7 doses of ACI-24 at 10μg at weeks 0, 4, 8, 12, 24, 36, and 48.

Cohort 2

Arm description

9 patients were planned to receive 7 doses of ACI-24 at 100μg at weeks 0, 4, 8, 12, 24, 36, and 48. Treatment period: 52 weeks Follow-up period: 100 weeks

Arm type

Experimental

Investigational medicinal product name

ACI-24

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

7 doses of ACI-24 at 100μg at weeks 0, 4, 8, 12, 24, 36, and 48.

Cohort 3

Arm description

9 patients of Cohort 3 were planned to receive 7 doses of ACI-24 at 300μg at weeks 0, 4, 8, 12, 24, 36, and 48. Treatment period: 52 weeks Follow-up period: 100 weeks Data of these Cohort 3 patients including the Treatment and Follow-up period is reported under Cohort 3. A boosting dose (dose 8) of ACI-24 at 300 µg was offered to Cohort 3 patients after the 100 weeks Follow-up period: - 3 patients received this boosting dose 2.5 to 3.25 years after the last injection received at week 48. Follow-up period after boosting dose: 24 weeks. Data of these Cohort 3 patients for the boosting procedure is reported under Cohort 3 Booster where applicable.

Arm type

Experimental

Investigational medicinal product name

ACI-24

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

7 doses of ACI-24 at 300μg at weeks 0, 4, 8, 12, 24, 36, and 48 and one boosting dose (dose 8) of ACI-24 at 300 µg 2.5 to 3.25 years after the last injection received at week 48 (if applicable).

Cohort 4

Arm description

9 patients of Cohort 4 were planned to receive 7 doses of ACI-24 at 1000μg at weeks 0, 4, 8, 12, 24, 36, and 48. Treatment period (7 doses): 52 weeks Follow-up period (7 doses): 100 weeks A boosting dose (dose 8) of ACI-24 at 1000μg at week 74 was offered to these patients: - 3 patients did not receive this boosting dose (2 patients did not give consent and treatment was discontinued in another patient after dose 6) and had Follow-up visits from week 64 to 152. These 3 patients plus the 9 patients until week 52 are reported under Cohort 4 (before/without Booster) where applicable. - 6 patients received this boosting dose and followed a different visit schedule from week 52. Treatment period (8 doses): 76 weeks Follow-up period (8 doses): 50 weeks Data of these patients from week 52 until study end is reported under Cohort 4 Booster where applicable. - Compiled data of Cohort 4 (before/without Booster) and Cohort 4 Booster is reported together under reporting group Cohort 4

Arm type

Experimental

Investigational medicinal product name

ACI-24

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

7 doses of ACI-24 at 1000μg at weeks 0, 4, 8, 12, 24, 36, and 48 and one boosting dose (dose 8) of ACI-24 at 1000μg at week 74 (if applicable). In Cohort 4, 2 concomitant injections were administered due to the higher volume of IMP needed.

Placebo

Arm description

The placebo patients of the 4 dose-cohorts (3 placebo patients per dose-cohort) are pooled to represent one group (a total of 12 placebo patients). Placebo patients followed the same visit/administration schedule as the corresponding actively treated patients in the same dose-cohort: Cohort 1, 2, 3, and 4: 3 patients per dose-cohort were planned to receive 7 doses of placebo at weeks 0, 4, 8, 12, 24, 36, and 48. A boosting dose (dose 8) of placebo was offered to patients in Cohorts 3 and 4: - In Cohort 3, 1 patient received this boosting dose of placebo 3 years after the last injection of week 48. Data of this patient from the boosting procedure is reported under Placebo in Cohort 3 Booster where applicable. - In Cohort 4, 1 patient received this boosting dose (dose 8) of placebo at week 74. Data of this patient from the boosting procedure is reported under Placebo in Cohort 4 Booster where applicable.

Arm type

Placebo

Investigational medicinal product name

Phosphate buffered saline (PBS)

Investigational medicinal product code

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

The volume of PBS administered to placebo patients was equivalent to the volume of ACI-24 administered to actively treated patients in each dose-cohort. In Cohort 4, 2 concomitant injections were administered due to the higher volume of IMP needed. Placebo patients followed the same visit/administration schedule as the corresponding actively treated patients in the same dose-cohort.

Number of subjects in period 1	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Placebo
Started	9	9	9	9	12
Completed	8	8	6	8	9
Not completed	1	1	3	1	3
Other	1	-	1	-	1
Death	-	1	-	-	1
Adverse event	-	-	-	1	-
Consent withdrawn	-	-	2	-	1

Baseline characteristics

Top of page

Reporting group title

Cohort 1

Reporting group description

9 patients were planned to receive 7 doses of ACI-24 at 10μg at weeks 0, 4, 8, 12, 24, 36, and 48. Treatment period: 52 weeks Follow-up period: 100 weeks

Reporting group title

Cohort 2

Reporting group description

9 patients were planned to receive 7 doses of ACI-24 at 100μg at weeks 0, 4, 8, 12, 24, 36, and 48. Treatment period: 52 weeks Follow-up period: 100 weeks

Reporting group title

Cohort 3

Reporting group description

Reporting group title

Cohort 4

Reporting group description

Reporting group title

Placebo

Reporting group description

Reporting group values	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Placebo	Total
Number of subjects	9	9	9	9	12	48
Age categorical
Units: Subjects
Adults (18-64 years)	3	5	1	5	2	16
From 65-84 years	6	4	8	4	10	32
Age continuous
Units: years
arithmetic mean (standard deviation)	69.4 ( 8.7 )	65.2 ( 8.3 )	71.1 ( 4.9 )	62.2 ( 8.5 )	69.1 ( 4.8 )	-
Gender categorical
Units: Subjects
Female	5	4	6	3	5	23
Male	4	5	3	6	7	25
Race
Units: Subjects
Hispanic or Latino	1	0	0	0	0	1
White	8	9	9	9	12	47

End points

Top of page

Reporting group title

Cohort 1

Reporting group description

9 patients were planned to receive 7 doses of ACI-24 at 10μg at weeks 0, 4, 8, 12, 24, 36, and 48. Treatment period: 52 weeks Follow-up period: 100 weeks

Reporting group title

Cohort 2

Reporting group description

9 patients were planned to receive 7 doses of ACI-24 at 100μg at weeks 0, 4, 8, 12, 24, 36, and 48. Treatment period: 52 weeks Follow-up period: 100 weeks

Reporting group title

Cohort 3

Reporting group description

Reporting group title

Cohort 4

Reporting group description

Reporting group title

Placebo

Reporting group description

Subject analysis set title

Cohort 3 Booster (Safety Analysis Set)

Subject analysis set type

Safety analysis

Subject analysis set description

Cohort 3 Booster (Safety Analysis Set) (3 patients who received a boosting dose (dose 8) of ACI-24 at 300μg 2.5 to 3.25 years after the last injection of week 48). Safety events that occurred after booster injection are reported.

Subject analysis set title

Placebo in Cohort 3 Booster (Safety Analysis Set)

Subject analysis set type

Safety analysis

Subject analysis set description

Placebo in Cohort 3 Booster (Safety Analysis Set) (1 patient who received a boosting dose (dose 8) of placebo 3 years after the last injection of week 48). Safety events that occurred after booster injection are reported.

Subject analysis set title

Cohort 4 Booster (Safety Analysis Set)

Subject analysis set type

Safety analysis

Subject analysis set description

Cohort 4 Booster (Safety Analysis Set) (6 patients who received a boosting dose (dose 8) of ACI-24 at 1000 μg at week 74). These patients followed a different visit schedule from week 52 than Cohort 4 patients who did not receive a boosting dose. Treatment period (8 doses): 76 weeks Follow-up period (8 doses): 50 weeks Data of these patients from week 52 until study end is reported.

Subject analysis set title

Placebo in Cohort 4 Booster (Safety Analysis Set)

Subject analysis set type

Safety analysis

Subject analysis set description

Placebo in Cohort 4 Booster (Safety Analysis Set) (1 patient who received a boosting dose (dose 8) of placebo at week 74. One patient of the other 2 patients did not consent for a boosting dose and the other patient died during the study). This patient followed a different visit schedule from week 52 than Cohort 4 patients who did not receive a boosting dose. Treatment period (8 doses): 76 weeks Follow-up period (8 doses): 50 weeks Data of this patient from week 52 until study end is reported.

Subject analysis set title

Cohort 4 Booster (Full Analysis Set)

Subject analysis set type

Full analysis

Subject analysis set description

Subject analysis set title

Cohort 4 (before/without Booster) (Full Analysis Set)

Subject analysis set type

Full analysis

Subject analysis set description

This reporting group comprises data of 9 patients of Cohort 4 until week 52 (9 patients who were planned to receive 7 doses of ACI-24 at 1000μg at weeks 0, 4, 8, 12, 24, 36, and 48) as well as data of 3 patients of Cohort 4 who did not receive a boosting dose who had additional Follow-up visit from week 64 to 152 (Follow-up period: 100 weeks). Of these 3 patients, 2 patients did not give consent for a boosting dose and treatment was discontinued in another patient after dose 6. Data of the other 6 patients (out of 9 patients) of Cohort 4 who received a boosting dose (dose 8) is not included in this reporting group. These patients followed a different visit schedule from week 52 and are reported under Cohort 4 Booster.

Subject analysis set title

Placebo in Cohort 4 Booster (Full Analysis Set)

Subject analysis set type

Full analysis

Subject analysis set description

Placebo in Cohort 4 Booster (Safety Analysis Set) (1 patient who received a boosting dose (dose 8) of placebo at week 74. Of the other 2 patients, 1 patient did not consent for a boosting dose and the other patient died during the study). This patient followed a different visit schedule from week 52 than Cohort 4 patients who did not receive a boosting dose. Treatment period (8 doses): 76 weeks Follow-up period (8 doses): 50 weeks Data of this patient from week 52 until study end is reported.

Primary: Overview of Adverse Events (Safety Analysis Set)

Top of page

End point title

Overview of Adverse Events (Safety Analysis Set) ^[1]

End point description

No hypothesis testing performed. Observations are given for the safety population (all randomized patients who received at least one dose of ACI-24 or placebo and who have at least one post-dosing safety assessment). Safety events that occurred during the Booster procedure in Cohort 3 are listed separately in the table. Categorical data are presented with the number of patients with at least one event for the following selections: - Treatment-emergent adverse events (TEAEs) - Deaths - Serious TEAEs - TEAEs leading to withdrawal of IMP - Severe and life threatening adverse events (AEs) - TEAEs possibly/probably related to IMP - Serious TEAEs possibly/probably related to IMP

End point type

Primary

End point timeframe

The safety reporting period was defined as the interval between the time of first dosing and the end of the designated Follow-up period. Adverse events falling into this time window were classified as treatment-emergent Adverse Events (TEAEs).

Notes
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: All data obtained in this study are listed and summarized with descriptive statistics or frequency tables where appropriate. No hypothesis testings have been performed as per the statistical analysis plan.

End point values	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Placebo	Cohort 3 Booster (Safety Analysis Set)	Placebo in Cohort 3 Booster (Safety Analysis Set)
Number of subjects analysed	9	9	9	9	12	3	1
Units: Number of patients
Treatment-emergent adverse events (TEAEs)	8	9	9	9	12	2	1
Deaths	0	1	0	1	1	0	0
Serious TEAEs	2	1	0	3	4	0	0
TEAEs leading to withdrawal of IMP	0	0	0	1	0	0	0
Severe and life threatening AEs	1	1	0	3	3	0	0
TEAEs possibly/probably related to IMP	5	4	5	8	6	0	1
Serious TEAEs possibly/probably related to IMP	0	0	0	0	0	0	0

No statistical analyses for this end point

Primary: Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set)

Top of page

End point title

Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set) ^[2]

End point description

No hypothesis testing performed. Results are reported for the safety population (all randomized patients who received at least one dose of ACI-24 or placebo and who have at least one post-dosing safety assessment). Data for Cohorts 1-4 and Placebo until week 52 are reported in this table. Tolerability data are tabulated with descriptive statistics and counts. For each visit, the count of patients in the tolerability categories "very good", "good", and "moderate" are given. Tolerability was never assessed as "poor" and this category is therefore not listed. Note: The number of patients provided in the table ("number of subjects analysed") shows the number of patients planned to be analyzed. The actual number of patients analyzed per data point (week) is the sum of listed patients per data point (week). Data for patients of Cohort 3 and 4 who received dose 8 are reported in separate tables.

End point type

Primary

End point timeframe

Tolerability was assessed at weeks 2, 4, 6, 8, 10, 12, 14, 18, 24, 26, 30, 36, 38, 42, 48 & 52. In addition, Cohort 4 patients receiving dose 8 were assessed at weeks 74 & 76 and Cohort 3 patients receiving dose 8 at weeks 2, 4 & 12 after boosting dose.

Notes
[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: All data obtained in this study are listed and summarized with descriptive statistics or frequency tables where appropriate. No hypothesis testings have been performed as per the statistical analysis plan.

End point values	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Placebo
Number of subjects analysed	9	9	9	9	12
Units: Number of patients
Week 2 – Very Good	8	8	7	5	7
Week 2 – Good	1	1	2	4	5
Week 2 – Moderate	0	0	0	0	0
Week 4 – Very Good	9	8	7	3	9
Week 4 – Good	0	1	2	6	3
Week 4 – Moderate	0	0	0	0	0
Week 6 – Very Good	8	9	8	5	9
Week 6 – Good	1	0	1	4	3
Week 6 – Moderate	0	0	0	0	0
Week 8 – Very Good	8	7	7	6	8
Week 8 – Good	1	2	2	3	4
Week 8 – Moderate	0	0	0	0	0
Week 10 – Very Good	9	6	7	2	6
Week 10 – Good	0	3	1	4	5
Week 10 – Moderate	0	0	1	0	0
Week 12 – Very Good	9	6	7	4	8
Week 12 – Good	0	3	2	5	4
Week 12 – Moderate	0	0	0	0	0
Week 14 – Very Good	8	6	7	4	8
Week 14 – Good	1	2	1	5	3
Week 14 – Moderate	0	1	1	0	0
Week 18 – Very Good	7	5	6	4	5
Week 18 – Good	1	2	3	5	6
Week 18 – Moderate	1	2	0	0	0
Week 24 – Very Good	7	7	7	4	6
Week 24 – Good	2	0	2	5	5
Week 24 – Moderate	0	2	0	0	0
Week 26 – Very Good	4	7	8	4	6
Week 26 – Good	5	0	1	5	4
Week 26 – Moderate	0	2	0	0	1
Week 30 – Very Good	6	7	5	4	7
Week 30 – Good	3	1	2	4	4
Week 30 – Moderate	0	1	1	1	0
Week 36 – Very Good	4	7	5	3	3
Week 36 – Good	4	1	4	5	8
Week 36 – Moderate	1	1	0	1	0
Week 38 – Very Good	5	6	6	3	6
Week 38 – Good	4	1	3	6	4
Week 38 – Moderate	0	2	0	0	0
Week 42 – Very Good	6	7	5	3	4
Week 42 – Good	3	1	2	6	5
Week 42 – Moderate	0	1	1	0	0
Week 48 – Very Good	3	6	7	1	3
Week 48 – Good	6	1	2	7	7
Week 48 – Moderate	0	2	0	0	0
Week 52 – Very Good	4	6	8	3	3
Week 52 – Good	5	3	1	6	6
Week 52 – Moderate	0	0	0	0	1

No statistical analyses for this end point

Primary: Global assessment of tolerability in Cohort 3 Booster and Placebo in Cohort 3 Booster (Safety Analysis Set)

Top of page

End point title

Global assessment of tolerability in Cohort 3 Booster and Placebo in Cohort 3 Booster (Safety Analysis Set) ^[3]

End point description

Please refer to the description for the end point “Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set)”.

End point type

Primary

End point timeframe

As stated above (end point “Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set)”), tolerability in Cohort 3 Booster patients who received dose 8 (ACI-24 or placebo) was assessed at weeks 2, 4 & 12 after boosting dose.

Notes
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: All data obtained in this study are listed and summarized with descriptive statistics or frequency tables where appropriate. No hypothesis testings have been performed as per the statistical analysis plan.

End point values	Cohort 3 Booster (Safety Analysis Set)	Placebo in Cohort 3 Booster (Safety Analysis Set)
Number of subjects analysed	3	1
Units: Number of patients
Week 2 – Very Good	2	0
Week 2 – Good	0	0
Week 2 – Moderate	1	1
Week 4 – Very Good	3	0
Week 4 – Good	0	1
Week 4 – Moderate	0	0
Week 12 – Very Good	3	0
Week 12 – Good	0	1
Week 12 – Moderate	0	0

No statistical analyses for this end point

Primary: Global assessment of tolerability in Cohort 4 Booster and Placebo in Cohort 4 Booster (Safety Analysis Set)

Top of page

End point title

Global assessment of tolerability in Cohort 4 Booster and Placebo in Cohort 4 Booster (Safety Analysis Set) ^[4]

End point description

Please refer to the description for the end point “Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set)”.

End point type

Primary

End point timeframe

As stated above (end point “Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set)”), tolerability in Cohort 4 patients who received dose 8 (ACI-24 or placebo) was assessed at weeks 74 & 76.

Notes
[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: All data obtained in this study are listed and summarized with descriptive statistics or frequency tables where appropriate. No hypothesis testings have been performed as per the statistical analysis plan.

End point values	Cohort 4 Booster (Safety Analysis Set)	Placebo in Cohort 4 Booster (Safety Analysis Set)
Number of subjects analysed	6	1
Units: Number of patients
Week 74 – Very Good	2	0
Week 74 – Good	3	1
Week 74 – Moderate	0	0
Week 76 – Very Good	2	0
Week 76 – Good	4	0
Week 76 – Moderate	0	1

No statistical analyses for this end point

Primary: Descriptive measures of anti-Abeta1-42 IgG in serum: Responder analysis (Full Analysis Set)

Top of page

End point title

Descriptive measures of anti-Abeta1-42 IgG in serum: Responder analysis (Full Analysis Set) ^[5]

End point description

The Aβ1-42 IgG antibody response in serum was studied in patients at the prespecified timepoints of Week 26 and Week 52 by enzyme-linked immunosorbent assay (ELISA) detecting the free fraction of IgG response. A patient was defined as a responder if the antibody response at 26 and/or 52 weeks of treatment was at least doubled compared to the Baseline value of antibody response. The Baseline value was defined as the mean of the anti-Aβ1-42 IgG titer values at the Screening Visit (Week -4 to 0) and visit 1 (Week 0). Note: The number of patients provided in the table ("number of subjects analysed") shows the number of patients planned to be analyzed. Table does not allow entering the number of patients analyzed per data point (actual numbers are recorded below). Actual number of patients analyzed (n): - at Week 26: n = 9 (Cohort 1, Cohort 2, Cohort 3, Cohort 4), n = 11 (Placebo) - at Week 52: n = 9 (Cohort 1, Cohort 2, Cohort 4), n = 8 (Cohort 3, Placebo)

End point type

Primary

End point timeframe

End point was assessed at weeks 26 and 52 after first dose.

Notes
[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: All data obtained in this study are listed and summarized with descriptive statistics or frequency tables where appropriate. No hypothesis testings have been performed as per the statistical analysis plan.

End point values	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Placebo
Number of subjects analysed	9	9	9	9	12
Units: Number of patients
Week 26 – IgG Responder	0	0	0	0	0
Week 52 – IgG Responder	0	0	1	0	0

No statistical analyses for this end point

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohorts 1-4 and Placebo (Full Analysis Set)

Top of page

End point title

Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohorts 1-4 and Placebo (Full Analysis Set) ^[6]

End point description

The brain Aβ levels were quantified by Amyloid Positron Emission Tomography (PET) using Florbetaben as the PET tracer at 3 different time points (Baseline or Screening (weeks -4 or week 0) and 2 later timepoints (weeks 26 & 52 or weeks 52 & 76) depending on the cohort/patient). The change from Baseline in composite summary (CompSum) Standardized Uptake Value Ratio (SUVR) using the Mean Cerebellum Gray (MCG) as reference region is tabulated. Note: The number of patients provided in the table ("number of subjects analysed") shows the number of patients planned to be analyzed. Table does not allow entering the number of patients analyzed per data point (actual numbers are recorded below). Actual number of patients analyzed (n): - at Week 26: n = 9 (Cohort 2-3), n = 3 (Cohort 4), n = 7 (Placebo) - at Week 52: n = 9 (Cohort 2-3), n = 7 (Cohort 4), n = 8 (Placebo) Data of patients in Cohort 4 Booster is listed in a separate table. PET Imaging was not done in Cohort 1.

End point type

Secondary

End point timeframe

Cohorts 2-3 patients were planned to be scanned at weeks 0, 26 & 52. Patients 1-4 in Cohort 4 were planned to be scanned at weeks -4 (Screening), 26 & 52. Patients 5-12 in Cohort 4 were planned to be scanned at weeks -4 (Screening), 52 & 76.

Notes
[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: All data obtained in this study are listed and summarized with descriptive statistics or frequency tables where appropriate. No hypothesis testings have been performed as per the statistical analysis plan.

End point values	Cohort 2	Cohort 3	Placebo	Cohort 4 (before/without Booster) (Full Analysis Set)
Number of subjects analysed	9	9	12	9
Units: Composite Summary SUVR (MCG)
arithmetic mean (standard deviation)
Change from Baseline (CompSum SUVR) – Week 26	0.02 ( 0.21 )	0.02 ( 0.19 )	0.02 ( 0.28 )	-0.10 ( 0.10 )
Change from Baseline (CompSum SUVR) – Week 52	0.08 ( 0.25 )	-0.03 ( 0.22 )	0.06 ( 0.22 )	-0.07 ( 0.07 )

No statistical analyses for this end point

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohort 4 Booster and Placebo in Cohort 4 Booster at Week 76 (Full Analysis Set)

Top of page

End point title

Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohort 4 Booster and Placebo in Cohort 4 Booster at Week 76 (Full Analysis Set)

End point description

Please refer to the description for the end point "Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohorts 1-4 and Placebo (Full Analysis Set)". Note: The number of patients in the table ("number of subjects analysed") shows the actual number of patients analyzed at week 76. As data for only 1 placebo patient is available, a standard deviation (SD) is not applicable. Since the table does not allow to enter "not applicable", a "0.0" was entered as SD for the placebo patient.

End point type

Secondary

End point timeframe

As stated above (end point "Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohorts 1-4 and Placebo (Full Analysis Set)", Cohort 4 patients 5-12 were planned to be scanned at Week 76.

End point values	Cohort 4 Booster (Full Analysis Set)	Placebo in Cohort 4 Booster (Full Analysis Set)
Number of subjects analysed	4	1
Units: Composite Summary SUVR (MCG)
arithmetic mean (standard deviation)
Change from Baseline (CompSum SUVR) – Week 76	0.06 ( 0.11 )	-0.17 ( 0.0 )

No statistical analyses for this end point

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohorts 1-4 and Placebo (Full Analysis Set)

Top of page

End point title

Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohorts 1-4 and Placebo (Full Analysis Set) ^[7]

End point description

The CDR was assessed in 6 categories: memory, orientation, judgement/problem solving, community affairs, home/hobbies, personal care. It is based on a semi-structured interview conducted with the patient and caregiver, by a rater without access to the results of the cognitive tests. Each category has scores from 0 (no symptoms) to 3 (severe), and the sum of these items (sum of boxes) may range from 0 to 18 points. An increase in the CDR - SB indicates a decline in functioning. The change from Baseline in CDR - SB is tabulated. Note: The number of patients provided in the table ("number of subjects analysed") shows the number of patients planned to be analyzed. Table does not allow entering the number of patients analyzed per data point, for the actual number of patients analyzed per data point refer to the attachment. Data for Cohort 4 Booster is presented in a separate table. Data for Cohort 3 Booster is not presented due to the small sample size.

End point type

Secondary

End point timeframe

The Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) was assessed at weeks 0, 26, 36, 52, 76, 100 & 152 (Cohorts 1-3 and 4 (before/without Booster)). Patients in Cohort 4 Booster were assessed at weeks 76, 87, 100 & 126.

Notes
[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: All data obtained in this study are listed and summarized with descriptive statistics or frequency tables where appropriate. No hypothesis testings have been performed as per the statistical analysis plan.

End point values	Cohort 1	Cohort 2	Cohort 3	Placebo	Cohort 4 (before/without Booster) (Full Analysis Set)
Number of subjects analysed	9	9	9	12	9
Units: CDR – SB
arithmetic mean (standard deviation)
Change from Baseline (CDR-SB) – Week 26	1.8 ( 1.7 )	0.6 ( 1.5 )	0.8 ( 1.3 )	1.1 ( 1.3 )	0.1 ( 0.5 )
Change from Baseline (CDR-SB) – Week 36	2.3 ( 1.6 )	1.3 ( 2.7 )	0.7 ( 0.8 )	1.4 ( 2.4 )	0.3 ( 0.8 )
Change from Baseline (CDR-SB) – Week 52	2.9 ( 2.0 )	2.6 ( 3.6 )	0.9 ( 1.7 )	2.0 ( 2.9 )	1.0 ( 1.0 )
Change from Baseline (CDR-SB) – Week 76	3.5 ( 3.0 )	3.4 ( 4.2 )	1.9 ( 1.8 )	3.9 ( 4.3 )	1.7 ( 0.8 )
Change from Baseline (CDR-SB) – Week 100	5.7 ( 2.5 )	3.6 ( 3.9 )	3.1 ( 2.5 )	4.4 ( 4.7 )	3.0 ( 2.1 )
Change from Baseline (CDR-SB) – Week 152	7.2 ( 3.5 )	4.4 ( 2.9 )	5.4 ( 4.0 )	4.4 ( 3.7 )	8.5 ( 0.0 )

Attachments

Attachment_CDR-Sum of boxes (FAS)

No statistical analyses for this end point

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Top of page

End point title

Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

End point description

Please refer to the description for the end point "Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohorts 1-4 and Placebo (Full Analysis Set)". Note: As data for only 1 placebo patient is available, a standard deviation (SD) is not applicable. Since the table does not allow to enter "not applicable", a "0.0" was entered as SD for the placebo patient.

End point type

Secondary

End point timeframe

As stated above (end point "Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohorts 1-4 and Placebo (Full Analysis Set)", patients in Cohort 4 Booster were assessed at weeks 76, 87, 100 & 126.

End point values	Cohort 4 Booster (Full Analysis Set)	Placebo in Cohort 4 Booster (Full Analysis Set)
Number of subjects analysed	6	1
Units: CDR – SB
arithmetic mean (standard deviation)
Change from Baseline (CDR-SB) – Week 76	1.0 ( 1.4 )	5.0 ( 0.0 )
Change from Baseline (CDR-SB) – Week 87	1.1 ( 1.2 )	4.0 ( 0.0 )
Change from Baseline (CDR-SB) – Week 100	1.4 ( 1.7 )	6.0 ( 0.0 )
Change from Baseline (CDR-SB) – Week 126	3.1 ( 3.4 )	7.0 ( 0.0 )

No statistical analyses for this end point

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohorts 1-4 and Placebo (Full Analysis Set)

Top of page

End point title

Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohorts 1-4 and Placebo (Full Analysis Set) ^[8]

End point description

The MMSE was performed to evaluate cognitive function, assessing memory, orientation, and praxis in a short series of tests. The score is from 0 to 30 with 30 being the best possible and 0 being the worst possible score. The change from Baseline in MMSE total scores is tabulated. Note: The number of patients provided in the table ("number of subjects analysed") shows the number of patients planned to be analyzed. Table does not allow entering the number of patients analyzed per data point, for the actual number of patients analyzed per data point refer to the attachment. Data for Cohort 4 Booster is presented in a separate table. Data for Cohort 3 Booster is not presented due to the small sample size.

End point type

Secondary

End point timeframe

The Mini-Mental State Examination (MMSE) was performed at weeks -4, 0, 26, 36, 52, 76, 100 & 152 (Cohorts 1-3 and 4 (before/without Booster)). Patients in Cohort 4 Booster were assessed at weeks 76, 87, 100 & 126.

Notes
[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: All data obtained in this study are listed and summarized with descriptive statistics or frequency tables where appropriate. No hypothesis testings have been performed as per the statistical analysis plan.

End point values	Cohort 1	Cohort 2	Cohort 3	Placebo	Cohort 4 (before/without Booster) (Full Analysis Set)
Number of subjects analysed	9	9	9	12	9
Units: MMSE total score
arithmetic mean (standard deviation)
Change from Baseline (MMSE total score) – Week 26	-2.9 ( 2.0 )	-2.1 ( 3.6 )	-1.3 ( 1.2 )	-1.3 ( 3.3 )	0.8 ( 1.4 )
Change from Baseline (MMSE total score) – Week 36	-4.5 ( 3.4 )	-2.0 ( 2.8 )	-2.1 ( 1.9 )	-1.5 ( 3.3 )	0.8 ( 1.4 )
Change from Baseline (MMSE total score) – Week 52	-3.0 ( 4.4 )	-2.9 ( 5.6 )	-3.0 ( 3.3 )	-2.9 ( 2.1 )	0.2 ( 1.9 )
Change from Baseline (MMSE total score) – Week 76	-4.4 ( 4.3 )	-3.9 ( 2.3 )	-5.1 ( 3.4 )	-4.4 ( 2.5 )	-1.7 ( 2.9 )
Change from Baseline (MMSE total score) – Week 100	-6.4 ( 4.0 )	-4.3 ( 2.3 )	-5.9 ( 2.6 )	-7.1 ( 3.8 )	-2.5 ( 2.1 )
Change from Baseline (MMSE total score) – Week 152	-10.0 ( 4.7 )	-8.5 ( 4.1 )	-6.2 ( 4.2 )	-9.1 ( 3.2 )	-11 ( 0.0 )

Attachments

Attachment_MMSE (FAS)

No statistical analyses for this end point

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Top of page

End point title

Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

End point description

Please refer to the description for the end point "Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohorts 1-4 and Placebo (Full Analysis Set)". Note: As data for only 1 placebo patient is available, a standard deviation (SD) is not applicable. Since the table does not allow to enter "not applicable", a "0.0" was entered as SD for the placebo patient.

End point type

Secondary

End point timeframe

As stated above (end point "Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohorts 1-4 and Placebo (Full Analysis Set)", patients in Cohort 4 Booster were assessed at weeks 76, 87, 100 & 126.

End point values	Cohort 4 Booster (Full Analysis Set)	Placebo in Cohort 4 Booster (Full Analysis Set)
Number of subjects analysed	6	1
Units: MMSE total score
arithmetic mean (standard deviation)
Change from Baseline (MMSE total score) – Week 76	-0.2 ( 1.9 )	-2.0 ( 0.0 )
Change from Baseline (MMSE total score) – Week 87	-1.8 ( 4.0 )	-3.0 ( 0.0 )
Change from Baseline (MMSE total score) – Week 100	-0.8 ( 2.6 )	1.0 ( 0.0 )
Change from Baseline (MMSE total score) – Week 126	-3.0 ( 4.4 )	-9.0 ( 0.0 )

No statistical analyses for this end point

Adverse events

Top of page

Timeframe for reporting adverse events

For the purpose of safety reporting, the study period was defined as the interval between the time of first dosing and the end of the designated Follow-up period.

Adverse event reporting additional description

Determination of AEs was based on: - the signs or symptoms detected during the physical examination and on clinical evaluation of the patient - the interview of the patient and their caregiver

Assessment type

Systematic

Dictionary name

MedDRA

Dictionary version

14.1

Reporting group title

Cohort 1 (Safety Analysis Set)

Reporting group description

Cohort 1 Safety Analysis Set (9 patients who received at least 1 dose of ACI-24 at 10μg)

Reporting group title

Cohort 2 (Safety Analysis Set)

Reporting group description

Cohort 2 Safety Analysis Set (9 patients who received at least 1 dose of ACI-24 at 100μg)

Reporting group title

Cohort 3 (Safety Analysis Set)

Reporting group description

Cohort 3 Safety Analysis Set (9 patients who received at least 1 dose of ACI-24 at 300μg)

Reporting group title

Cohort 4 (Safety Analysis Set)

Reporting group description

Cohort 4 Safety Analysis Set (9 patients who received at least 1 dose of ACI-24 at 1000μg). Note: For 1 patient the SAE "Neoplasm malignant" was reported during the study. This patient completed the study but died shortly (arround 1 month) after the last safety Follow-up visit. Although this event (Death) did not occur in the official safety reporting period of the study, this outcome is however reported in the table for SAEs.

Reporting group title

Placebo (pooled) (Safety Analysis Set)

Reporting group description

Placebo (pooled) Safety Analysis Set (12 patients who received at least 1 dose of placebo)

Reporting group title

Cohort 3 Booster (Safety Analysis Set)

Reporting group description

Cohort 3 Booster (Safety Analysis Set) (3 patients who received a boosting dose (dose 8) of ACI-24 at 300μg 2.5 to 3.25 years after the last injection received at week 48). Events that occurred after booster injection are reported.

Reporting group title

Placebo in Cohort 3 Booster (Safety Analysis Set)

Reporting group description

Placebo in Cohort 3 Booster (Safety Analysis Set) (1 patient who received a boosting dose (dose 8) of placebo 2.5 to 3.25 years after the last injection received at week 48). Events that occurred after booster injection are reported.

Serious adverse events	Cohort 1 (Safety Analysis Set)	Cohort 2 (Safety Analysis Set)	Cohort 3 (Safety Analysis Set)	Cohort 4 (Safety Analysis Set)	Placebo (pooled) (Safety Analysis Set)	Cohort 3 Booster (Safety Analysis Set)	Placebo in Cohort 3 Booster (Safety Analysis Set)
Total subjects affected by serious adverse events
subjects affected / exposed	2 / 9 (22.22%)	1 / 9 (11.11%)	0 / 9 (0.00%)	3 / 9 (33.33%)	4 / 12 (33.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
number of deaths (all causes)	0	1	0	1	1	0	0
number of deaths resulting from adverse events	0	1	0	1	1	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Colon cancer
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Neoplasm malignant
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications
Compression fracture
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Fall
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Wrist fracture
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions
Cardiac death
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0
Chest pain
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Death
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders
Inguinal hernia
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Pancreatitis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 3	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Infections and infestations
Pneumonia
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Wound infection
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5%

Non-serious adverse events	Cohort 1 (Safety Analysis Set)	Cohort 2 (Safety Analysis Set)	Cohort 3 (Safety Analysis Set)	Cohort 4 (Safety Analysis Set)	Placebo (pooled) (Safety Analysis Set)	Cohort 3 Booster (Safety Analysis Set)	Placebo in Cohort 3 Booster (Safety Analysis Set)
Total subjects affected by non serious adverse events
subjects affected / exposed	8 / 9 (88.89%)	9 / 9 (100.00%)	9 / 9 (100.00%)	9 / 9 (100.00%)	12 / 12 (100.00%)	2 / 3 (66.67%)	1 / 1 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Colon cancer
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Keratoacanthoma
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Leiomyoma
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Neoplasm malignant
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Prostate cancer
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Vascular disorders
Hypertension
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	1	0	3	0	0	0
Hypotension
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	1	0
Thrombophlebitis superficial
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Vein disorder
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Surgical and medical procedures
Hernia repair
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Hip arthroplasty
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	3	0	0
Tooth extraction
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	2	0	0	0	0	0	0
General disorders and administration site conditions
Cardiac death
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Chest discomfort
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Chest pain
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	1	0	1	0	0	0
Death
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Fatigue
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	5 / 9 (55.56%)	3 / 12 (25.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	1	10	4	0	0
Feeling cold
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Injection site erythema
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	3	0	0	0
Injection site haemorrhage
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Injection site reaction
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Injection site swelling
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	3	0	0	0
Irritability
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	1	1	0	0	0
Malaise
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	7	0	0	0
Nodule
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Oedema peripheral
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Pyrexia
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	1	0	0	0	0
Ulcer
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	1	0	0
Immune system disorders
Hypersensitivity
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	1 / 1 (100.00%)
occurrences all number	0	0	0	0	1	0	1
Respiratory, thoracic and mediastinal disorders
Asthma
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Cough
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	2	0	0	0
Dysphonia
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Oropharyngeal pain
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Rales
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Psychiatric disorders
Abnormal behaviour
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	2	0	0
Affective disorder
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Aggression
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Agitation
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	1 / 1 (100.00%)
occurrences all number	0	0	1	0	1	0	1
Anger
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Anxiety
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	2	1	0	0
Confusional state
subjects affected / exposed	2 / 9 (22.22%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	1 / 1 (100.00%)
occurrences all number	2	2	1	0	1	0	1
Delirium
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Delusion
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	1	0	0	0
Depression
subjects affected / exposed	0 / 9 (0.00%)	3 / 9 (33.33%)	0 / 9 (0.00%)	1 / 9 (11.11%)	3 / 12 (25.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	3	0	1	3	0	0
Depressive symptom
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	1	1	1	0	0
Erectile dysfunction
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Hallucination
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	2	0	0	0	0	0	0
Hallucination, auditory
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Hallucination, visual
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	1	0	0
Insomnia
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	2	1	1	0	0
Rapid eye movements sleep abnormal
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	3	0	0
Restlessness
subjects affected / exposed	2 / 9 (22.22%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	2	0	1	1	0	0	0
Sleep disorder
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	2	0	0	0	0	0
Investigations
Alanine aminotransferase increased
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Aspartate aminotransferase increased
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Blood acid phosphatase increased
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Blood creatine phosphokinase increased
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Blood creatinine increased
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 12 (16.67%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	2	0	0
C-reactive protein increased
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	2	0	0	0
Weight decreased
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Injury, poisoning and procedural complications
Arthropod bite
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Compression fracture
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Contusion
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	2	0	0	0	1	0	0
Fall
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	2	0	1	1	1	0	0
Ligament sprain
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Limb injury
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Post lumbar puncture syndrome
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	2	0	0	0	0	0
Radius fracture
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Road traffic accident
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Thermal burn
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	1	0	0	0	0	0
Wound
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Wrist fracture
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	1	0	0
Cardiac disorders
Extrasystoles
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Nervous system disorders
Balance disorder
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	2	0	0
Cognitive disorder
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Dementia Alzheimer's type
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	1	0	0
Dizziness
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	3 / 12 (25.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	1	0	3	0	0
Dyskinesia
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Head titubation
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Headache
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	2 / 9 (22.22%)	4 / 9 (44.44%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	3	14	1	0	0
Hypoaesthesia
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	2	0	0	0	0	0
Lacunar infarction
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Memory impairment
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Parkinson's disease
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Presyncope
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Sensory disturbance
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Syncope
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Ear and labyrinth disorders
Vertigo
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	2	0	1	0	0
Vertigo positional
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Eye disorders
Accommodation disorder
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Conjunctival haemorrhage
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Macular degeneration
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Visual acuity reduced
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Vitreous detachment
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Gastrointestinal disorders
Abdominal discomfort
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Abdominal pain
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	1	0	0
Abdominal pain upper
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	1	0	0
Constipation
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	1	1	0	0	0	0
Diarrhoea
subjects affected / exposed	3 / 9 (33.33%)	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)	3 / 12 (25.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	4	1	0	1	3	0	0
Dyspepsia
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	1	0	0
Haematochezia
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Haemorrhoidal haemorrhage
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Inguinal hernia
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	1	0	0	0
Nausea
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	2	1	4	1	0	0
Pancreatitis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	3	0	0	0
Paraesthesia oral
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Salivary hypersecretion
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Vomiting
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	2 / 9 (22.22%)	1 / 9 (11.11%)	2 / 12 (16.67%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	2	3	2	0	0
Vomiting projectile
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Hepatobiliary disorders
Cholelithiasis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Skin and subcutaneous tissue disorders
Actinic keratosis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	2	0	0	0	0
Blepharitis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Ecchymosis
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Eczema asteatotic
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Erythema
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 9 (11.11%)	2 / 12 (16.67%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	1	1	2	0	0
Hyperhidrosis
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	1	0	0
Night sweats
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0
Papule
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Rosacea
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Seborrhoeic dermatitis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Skin ulcer
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 1 (0.00%)
occurrences all number	0	1	1	0	0	1	0
Staphylococcal skin infection
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Musculoskeletal and connective tissue disorders
Arthralgia
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	1	1	0	0	0	0
Arthropathy
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Back pain
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	4	0	1	1	2	0	0
Costochondritis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Monarthritis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Muscle spasms
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	1	0	0	0
Musculoskeletal chest pain
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Musculoskeletal pain
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	2	0	0	0
Myalgia
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Neck pain
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Pain in extremity
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	2	0	0
Pain in jaw
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Periarthritis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Tendonitis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)	2 / 9 (22.22%)	0 / 12 (0.00%)	1 / 3 (33.33%)	0 / 1 (0.00%)
occurrences all number	0	0	2	2	0	1	0
Infections and infestations
Bronchitis
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	2	0	0
Cystitis
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	2	0	0	0	0	0
Erythema migrans
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	2	0	0	0
Gastroenteritis
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	1	0	0	0
Gingival infection
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	2	0	0	0	0	0	0
Herpes virus infection
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Infection
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Influenza
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	1	0	0
Laryngitis
subjects affected / exposed	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	1	0	0	0	0	0
Nasopharyngitis
subjects affected / exposed	0 / 9 (0.00%)	2 / 9 (22.22%)	2 / 9 (22.22%)	4 / 9 (44.44%)	2 / 12 (16.67%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	3	3	6	2	0	0
Pneumonia
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	2	0	1	0	0	0	0
Tooth infection
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Urinary tract infection
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	2	1	1	0	0
Wound infection
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 12 (8.33%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	0	1	0	0
Metabolism and nutrition disorders
Decreased appetite
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Diabetes mellitus
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Gout
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	1	0	0	0	0
Hypoalbuminaemia
subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	0	0	0	1	0	0	0
Type 2 diabetes mellitus
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)	0 / 12 (0.00%)	0 / 3 (0.00%)	0 / 1 (0.00%)
occurrences all number	1	0	0	0	0	0	0

More information

Top of page

Were there any global substantial amendments to the protocol? Yes

25 Sep 2009

Amendment 2: Major Changes • Added a requirement for 24 hours of hospitalization after first IMP injection • Added the requirement to obtain approval before commencement of Step 2 Minor Changes • Updated study contact details and Sponsor Medical Director • Clarification on planned interim analysis provided

25 Sep 2009

Amendment 1: Major Changes • Added DSMB meetings for safety evaluation • Added T-cell measurement at V4 (Week 6) • Additional description of the Informed Consent procedure added • Added patient safety supervision and monitoring after injections • Included coagulation assessment prior to lumbar puncture • Defined randomization process (eg, the 4 first patients of each dose-cohort [Step 1], were randomized in an interval of more or equal (≥) than 7 days) • Removed cross-reactivity measurement • Removed PET imaging in the case of dose-Cohort 1 (10 μg) (Step 1) Minor Changes • Included additional investigational medicinal product storage information • Updated study contact details • Updated site personnel responsibilities regarding psychometric tests and Clinical rating scales • Re-organized psychometric test battery • Updated visits time window • Updated laboratory assessments and schedule

10 Sep 2010

Amendment 3: Major Changes • Removed EEG recording • Changed the ligand to be used for PET imaging

22 Mar 2011

Amendment 4: Major Changes • Added additional T-cell measurements at V2 (Week 2), V6 (Week 10), V11 (Week 26), and V14 (Week 38) • Addition of TLR4 expression assessments at V1 (Week 0) and 17 (Week 52) • Updated blood sample volumes to be taken Minor Changes • Added clarifications on wording • Updated study plan with new laboratory assessments • Updated study contact details

23 Sep 2011

Amendment 5: Major Changes • Addition of TLRs and NLRs expression assessments at V1 (Week 0) and 17 (Week 52) • Added clarification that vital signs were measured at every visit • Allowed the use of Memantine in the Follow-up period (after Week 52) • Addition of coagulation indices measurement at Screening visit • Updated blood sample volumes to be taken (10 mL for biomarkers assessments instead of 20 mL and 20 mL for T-cell profile assessment instead of 10 mL) Minor Changes • Added clarifications on wording

17 Jan 2012

Amendment 6: Minor Changes • Listed the changes of responsible persons/organizations and contact details

04 May 2012

Amendment 7: Minor Changes • Listed the changes of responsible persons/organizations and contact details

10 Jul 2012

Amendment 8: Major Changes • Added an interim analysis in Step 1 to see antibody anti-Aβ1-42 titers for all patients in Cohort 1 and patients of Cohort 2 up to 6 months of treatment • Updated patient information with additional details that further described the use of Florbetaben as radiolabeled agent in PET imaging

04 Oct 2013

Amendment 9: Major Changes • Replacement of PET imaging by measurement of Aβ1-42 in blood in the interim analysis at 26 weeks of treatment in the highest dose group and in all corresponding sections • Added clarification that the unblinding could have been done using the IVRS and there were no sealed code break envelops on site • Added a clarification on the SAE reporting procedure and safety officer email address • Updated the Data Handling section after the change of system from Oracle Clinical to Omnicomm Minor Changes • Included changes on the background information related to the IB update • Added clarification on the responsibilities on the packaging and labeling of investigational medicinal product • Added clarification that MRI was part of the Screening visit and not Baseline visit • Added clarifications on wording

18 Mar 2014

Amendment 10: Major Changes • Added Cohort 4 to assess the immunogenicity of a higher dose (1000 μg) of ACI-24 • Added PET imaging as an inclusion criterion • Added performance of Baseline CSF sampling at least 3 days prior to administration of investigational medicinal product Minor Changes • Change of safety reporting company to Product Life Ltd

04 Jul 2014

Amendment 11: Major Changes • Changed inclusion criterion number 2 with raising the MMSE upper limit from 26 to 28

02 Apr 2015

Amendment 12: Major Changes • Added analysis of additional testing in the first 4 patients of Cohort 4: Aβ1-42 and Aβ1-40 in plasma and Aβ1-42 in CSF; IgM anti-Aβ; inflammatory markers

26 Jun 2015

Amendment 13: Major Changes • Added analysis of additional testing in the 12 patients of Cohort 3: Aβ1-42 and Aβ1-40 in plasma and Aβ1-42 in CSF; IgM anti-Aβ in serum; inflammatory markers (cytokines)

30 Nov 2015

Amendment 14: Major Changes • Expanded Cohort 4 from 4 to 12 patients • Added a late booster injection at 18 months for patients in Cohort 4 • Added an inclusion criterion as requested by the Swedish MPA in order to comply with Swedish law 1992:859 13b §. This additional criterion was only applicable in Sweden. Minor Changes • Updated study contact details

03 Mar 2016

Amendment 15: Major Changes • Added a late booster injection at 2.5 to 3.25 years after last dose for patients in Cohort 3 Minor Changes • Corrected the visit schedule for Study Plan number 2 for Cohort 4 to state that PET imaging was done at the Screening Visit, not at V1

17 Oct 2016

Amendment 16: Major Changes • Clarified content for the full interim analysis of Step 1 data, namely: - to specify that subsequent Interim analyses could have been conducted if needed at later timepoints than V11 (Week 26) for all patients enrolled in Cohort 4 - planned to unblind data of patients participating in Cohort 1, 2, 3, and 4 after booster after data for these cohorts had been locked - all data available for any visit in all cohorts up to the data-cut date (ie, the last patient completing Week 26 in Cohort 4) was to be included in the full interim analysis • Implemented changes to improve consistency between sections of the study protocol, by clarifying the study objectives and endpoints classifications in Sections 7.1 and 7.2 of the study protocol • Clarified the term “Inflammatory marker” to delineate between collection of cytokines alone or cytokines and CRP • Clarified that the version of ADAS-Cog to be used was ADAS-Cog12 Minor Changes • A number of administrative changes were added, including modification of the contact list to include additional vendors and update information, modification of the headers in some pages to align with the section concerned, modification of the signature page, an update of Section 6.2, and clarification of what procedure/analysis was to be performed for each cohort when the wording was confusing

17 Jul 2017

Amendment 17: Minor Changes • Reduced the safety Follow-up period of patients in Cohort 4 who received a booster injection at 18 months from 2 years to 1 year

Were there any global interruptions to the trial? No

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Small sample size allowed only descriptive statistics.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Clinical trials

Clinical Trial Results:
A Phase I/II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity, and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Disease

Trial information

Trial information

Subject disposition

Subject disposition

Baseline characteristics

Baseline characteristics

End points

End points

Primary: Overview of Adverse Events (Safety Analysis Set)

Primary: Overview of Adverse Events (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohort 3 Booster and Placebo in Cohort 3 Booster (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohort 3 Booster and Placebo in Cohort 3 Booster (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohort 4 Booster and Placebo in Cohort 4 Booster (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohort 4 Booster and Placebo in Cohort 4 Booster (Safety Analysis Set)

Primary: Descriptive measures of anti-Abeta1-42 IgG in serum: Responder analysis (Full Analysis Set)

Primary: Descriptive measures of anti-Abeta1-42 IgG in serum: Responder analysis (Full Analysis Set)

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohort 4 Booster and Placebo in Cohort 4 Booster at Week 76 (Full Analysis Set)

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohort 4 Booster and Placebo in Cohort 4 Booster at Week 76 (Full Analysis Set)

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Adverse events

Adverse events

More information

Substantial protocol amendments (globally)

Interruptions (globally)

Limitations and caveats

More information

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials

Clinical Trial Results: A Phase I/II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity, and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Disease

Trial information

Trial information

Subject disposition

Subject disposition

Baseline characteristics

Baseline characteristics

End points

End points

Primary: Overview of Adverse Events (Safety Analysis Set)

Primary: Overview of Adverse Events (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohorts 1-4 and Placebo (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohort 3 Booster and Placebo in Cohort 3 Booster (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohort 3 Booster and Placebo in Cohort 3 Booster (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohort 4 Booster and Placebo in Cohort 4 Booster (Safety Analysis Set)

Primary: Global assessment of tolerability in Cohort 4 Booster and Placebo in Cohort 4 Booster (Safety Analysis Set)

Primary: Descriptive measures of anti-Abeta1-42 IgG in serum: Responder analysis (Full Analysis Set)

Primary: Descriptive measures of anti-Abeta1-42 IgG in serum: Responder analysis (Full Analysis Set)

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohort 4 Booster and Placebo in Cohort 4 Booster at Week 76 (Full Analysis Set)

Secondary: Descriptive measures of brain Aβ levels assessed by Positron Emission Tomography (PET) in Cohort 4 Booster and Placebo in Cohort 4 Booster at Week 76 (Full Analysis Set)

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Secondary: Assessment of global function as measured by the Clinical Dementia Rating (CDR) Scale - sum of boxes (SB) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohorts 1-4 and Placebo (Full Analysis Set)

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Secondary: Assessment of cognitive function as measured by Mini-Mental State Examination (MMSE) in Cohort 4 Booster and Placebo in Cohort 4 Booster (Full Analysis Set)

Adverse events

Adverse events

More information

Substantial protocol amendments (globally)

Interruptions (globally)

Limitations and caveats

More information

Clinical Trial Results:
A Phase I/II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity, and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Disease